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 Supplementary Table 1. Unit cost for individual surgical procedures. 
 
 Items Unit costs 
(£) 
Source 
Monitoring Monitor  95 Indicative manufacturer’s price 
Surgery Lower gastrointestinal (elective) 1,777 NHS Reference cost 
Upper gastrointestinal (elective) 2,854 NHS Reference cost 
Small bowel +/- pancreas (elective) 2,450 NHS Reference cost 
Urological or gynaecological (elective) 6,485 NHS Reference cost 
Aortic or Abdominal surgery (non-elective) 6,423 NHS Reference cost 
Blood & fluid Colloid (500 ml) 4.70 British National Formulary 
Crystalloid (1000 ml) 1.83 Personal communication 
Red cell (280 ml) 122.09 NHS Blood & Transplant 
Frozen fresh plasma (250 ml) 29.98 NHS Blood & Transplant 
Drug & other 
related  
Dopexamine (50 mg) 25.20 British National Formulary 
Syringe 0.36 Personal communication 
Giving set 1.53 Personal communication 
Saline 2.30 Personal communication 
Hospital costs Critical care level 2 868 NHS Reference cost 
Critical care level 3 1,416 NHS Reference cost 





Supplementary Table 2. Hospital costs (£) up to six months in the trial intervention groups.  
Data presented as mean (SD).  
 










Surgery costs 2,453 (999) 2,440 (1019) 
Intervention   
    Cardiac monitor costs 94 (10) 8 (27) 
    Drug (Dopexamine) costs 28 (6) - 
    Intravenous crystalloid costs 5 (3) 7 (3) 
    Intravenous colloid costs 21 (11) 9 (8) 
    Blood products costs 82 (379) 39 (205) 
Critical care costs 3,202 (4,111) 3,519 (5,598) 
General surgical ward costs 2,687 (3,751) 2,952 (3,267) 
Total costs 8,574 (6,304) 8,974 (7,217) 
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Supplementary Table 3. Subgroup analyses reporting incremental costs (£), quality 
adjusted life years (QALYs) and incremental net benefit at six months. 
Data presented as mean (95% confidence intervals). *Incremental effects are adjusted for baseline variables 












(-1,313 to 505) 
0.01 
(0.00 to 0.02) 
580 
(-378 to 1,583) 
Urgency of surgery    
 Elective (n=708) 
-416 
(-1,327 to 496) 
0.01 
(0.00 to 0.02) 
579 
(-383 to 1,541) 
 Non-elective (n=25) 
-3,042 
(-11,026 to 4,942) 
-0.02 
(-0.08 to 0.05) 
2,733 
(-5,091 to 10,557) 
Type of surgery    
 Upper gastro (n=222) 
-273 
(-2,361 to 1,815) 
0.01 
(-0.01 to 0.03) 
454 
(-1,699 to 2,607) 
 Lower gastro (n=334) 
-796 
(-1,903 to 311) 
0.01 
(-0.01 to 0.02) 
906 
(-272 to 2,083) 
 Small bowel +/- pancreas (n=168) 
256 
(-1,430 to 1,943) 
0.01 
(-0.01 to 0.04) 
3 
(-1,808 to 1,814) 
Timing of recruitment    
 Early (n=160) 
879 
(-1,257 to 3,015) 
-0.02 
(-0.04 to 0.01) 
-1,207 
(-3,442 to 1,028) 
 Late (n=565) 
-821 
(-1,840 to 197) 
0.02 
(0.00 to 0.03) 
1,133 




Supplementary Table 4. Goodness of fit of statistical models based on alternative 
distributions of survival functions. 
 
 
Distribution Akaike Information Criteria 
Gompertz 1476.3 
Lognormal 1509.3     








Supplementary Table 5. Ratios (with 95% confidence intervals) of the mortality rates from 
applying alternative parametric extrapolations for OPTIMISE patients compared with the 
age-gender matched general population. 
 
 































































Supplementary Table 6. Sensitivity analyses reporting lifetime incremental costs (£), 
quality adjusted life years (QALYs), and incremental net benefit.  
Data presented as mean (95% confidence intervals). *Incremental effects are adjusted for baseline variables 
including all variables used in minimisation algorithm.  
 
 








(-1,313 to 504) 
0.19 
(-0.17 to 0.54) 
4,168 
(-3,063 to 11,398) 
Total costs including costs 
incurred in recovery unit 
-412 
(-1,319 to 495) 
0.19 
(-0.17 to 0.54) 
4,175 
(-3,056 to  11,405) 
Additional staff time for the 
intervention 
-216 
(-1,125 to 693) 
0.19 
(-0.17 to 0.54) 
3,979 
(-3,252 to  11,209) 
Alternative QoL assumption 
-405 
(-1,314 to 504) 
0.19 
(-0.16 to 0.55) 
4,289 
(-3,025 to  11,603) 
QALY calculation for decedents 
up to time of death  
-405 
(-1,314 to 504) 
0.18 
(-0.17 to 0.54) 
4,097 
(-3,184 to 11,379) 
QoL weights from OPTIMISE 
-405 
(-1,314 to 504) 
0.18 
(-0.14 to 0.50) 
4,053 
(-2,470 to  10,576) 
Weibull survival 
-405 
(-1,314 to 504) 
0.19 
(-0.17 to 0.54) 
4,163 




Supplementary Figure 1. Cost-effectiveness acceptability curve (all patient six months 
analysis) describing the probability that cardiac output-guided haemodynamic therapy is 
cost effective for a range of decision makers’ willingness to pay thresholds per quality-

















































Supplementary Figure 2. Kaplan-Meier survival curves of OPTIMISE patients stratified by 
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Supplementary Figure 3:  Population expected value of perfect information (EVPI) 
illustrating the expected value of perfect information that would resolve uncertainty 
regarding the treatment decision for a range of decision makers’ willingness to pay 
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